A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response

Chinyu G. Su,1 Xiaoming Wen,1 Shannon T. Bailey,2 Wen Jiang,1 Shamina M. Rangwala,2 Sue A. Keilbaugh,1 Anne Flanigan,3 Sreekant Murthy,3 Mitchell A. Lazar,2 and Gary D. Wu1

1Division of Gastroenterology, and
2Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
3Division of Gastroenterology and Hepatology, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA

Address correspondence and reprint requests to: Gary D. Wu, 600 Clinical Research Building, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104-6144, USA. Phone: (215) 898-0158; Fax: (215) 573-2024; E-mail: gdwu@mail.med.upenn.edu.
Chinyu G. Su and Xiaoming Wen contributed equally to this work.

Received for publication April 21, 1999, and accepted in revised form June 30, 1999.

Peroxisome proliferator-activated receptor γ (PPAR-γ), a member of the nuclear hormone receptor superfamily originally shown to play a critical role in adipocyte differentiation and glucose homeostasis, has recently been implicated as a regulator of cellular proliferation and inflammatory responses. Colonic epithelial cells, which express high levels of PPAR-γ protein, have the ability to produce inflammatory cytokines that may play a role in inflammatory bowel disease (IBD). We report here that PPAR-γ ligands dramatically attenuate cytokine gene expression in colon cancer cell lines by inhibiting the activation of nuclear factor-κB via an IκB-κB–dependent mechanism. Moreover, thiazolidinedione ligands for PPAR-γ markedly reduce colonic inflammation in a mouse model of IBD. These results suggest that colonic PPAR-γ may be a therapeutic target in humans suffering from IBD.


citation:


Introduction

Delicately balanced mechanisms maintain the intestinal mucosa in a quiescent state of inflammation. In humans, loss of this balance leads to inflammatory bowel disease (IBD), a chronic debilitating disease that affects millions of people worldwide. The intestinal inflammatory phenotype observed in many immune receptor and cytokine knockout mice models lends support to the notion that cytokines help to regulate and maintain this quiescent state (1). It is now apparent that the intestinal epithelium, which is the interface between the highly antigenic luminal environment and the mucosal immune system, plays an active role in the immune responsiveness of the intestinal mucosa. Intestinal epithelial cells not only express various immune receptors traditionally believed to be expressed primarily by myeloid cell lineages (2), but they can also produce a wide array of immunomodulatory substances such as cytokines and complement factors (3–5). Indeed, specific perturbation of the intestinal epithelium can lead to intestinal inflammation (6, 7).

Many immune response genes are regulated by homo- and heterodimeric complexes of the nuclear factor-κB/Rel (NF-κB/Rel) family of transcription factors. We have previously shown that binding of proteins to the NF-κB element in the IL-8 promoter is critical for IL-1β–mediated activation of this promoter in intestinal cell lines (8). In most cells, NF-κB/Rel factors are maintained in an inactive state in the cytoplasm bound to members of the IκB family of inhibitory proteins (9). Upon cell stimulation by a variety of immunomodulatory substances such as IL-1, TNF-α, PMA, or oxygen radicals, these IκB proteins are rapidly phosphorylated and degraded via the ubiquitin-proteosome pathway (10). This enables NF-κB/Rel proteins to translocate from the cytoplasm into the nucleus and activate gene transcription. Inhibitors of NF-κB activation, such as glucocorticoids, have been shown to be very potent anti-inflammatory agents (11).

Recently, ligands for the peroxisome proliferator-activated receptor γ (PPAR-γ) have been shown to inhibit the expression of various cytokines in monocytes and macrophages, principally by preventing the activation of NF-κB/Rel by an unknown mechanism (12, 13). PPAR-γ is a member of the nuclear hormone receptor superfamily whose ligands include several prostanoids including 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), polyunsaturated fatty acids, a variety of nonsteroidal anti-inflammatory drugs (NSAIDs), and a new class of oral antidiabetic agents, the thiazolidinediones (TZDs) (14–16). PPAR-γ ligands are best characterized as regulators of adipocyte differentiation and glucose homeostasis (17, 18).

PPAR-γ is also expressed at high levels in both the colonic epithelium and in colon cancer cell lines (19–23). The function of PPAR-γ in the colonic epithelium is currently unknown. This is reinforced by recent studies that report that PPAR-γ ligands can either increase or decrease colonocyte proliferation depending on the model system studied (21–24). Here we show that the role of PPAR-γ in the colon may not be solely, or even primarily, to regulate growth and differentiation, but rather to regulate immune responsiveness. PPAR-γ ligands dramatically interfere with the activation of NF-κB and the ability of

The Journal of Clinical Investigation | August 1999 | Volume 104 | Number 4 383
colonocytes to express immunomodulatory cytokines. Moreover, PPAR-γ ligands interfere with the colonic inflammatory process in vivo and, thus, have promise as preventive and therapeutic agents against IBD.

Methods

Cell culture. Caco-2 and HT-29 cells (American Type Culture Collection, Rockville, Maryland, USA) were maintained in DMEM containing 10% FBS and penicillin/streptomycin.

RNA analysis. Caco-2 and HT-29 cells were treated with various concentrations of 15d-PGJ2, BRL 49653, ethyl acetate, or DMSO for 24 hours. After RNA isolation and blotting, the Northern blots were hybridized with cDNA probes for IL-8, monocyte chemoattractant protein-1 (MCP-1), and ribosomal 7S (25).

Protein analysis. Proteins were isolated from cells in culture by suspension in RIPA buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 100 μg/mL PMSF, 60 μg/mL aprotinin, and 1 mM sodium orthovanadate. Cell lysates were centrifuged, and the supernatants were collected and subjected to Western analysis using a 1:200 dilution of an affinity-purified IκB-α antibody (sc-203; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA). After a wash in 1× TTBS containing 0.1% Tween and a 1-hour incubation at room temperature with a horseradish peroxidase–conjugated anti-rabbit antibody (1:5,000 dilution; Boehringer Mannheim Biochemicals, Indianapolis, Indiana, USA), the proteins were viewed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA).

Electrophoretic mobility shift assays (EMSAs) were performed using Caco-2 cells treated with either methyl acetate (solvent) or 15d-PGJ2 (30 μM) for 24 hours. The cells were stimulated with complete medium containing IL-1β (5 ng/mL) for various periods as indicated. Nuclear proteins were isolated from both unstimulated and IL-1β–stimulated Caco-2 cells. Double-stranded oligonucleotides spanning the NF-κB element of the IL-8 promoter (8) were labeled with 32P. Binding reactions, each containing 10 μg of nuclear proteins, were performed as described previously (26). Nuclear proteins were subsequently separated on a 4% polyacrylamide gel.

Transient cell transfections. Caco-2 cells were transiently cotransfected with either the IL-8 promoter luciferase reporter plasmid (wt)LUC (8) or the PPAR-γ–regulated reporter plasmid acyl-CoA X 3-TK-LUC (27) and pCMV-β-gal (transfection control), using the calcium phosphate precipitation method (28). Forty-eight hours after transfection, the cells were treated with various concentrations of 15d-PGJ2 for 24 hours. Cells were stimulated with IL-1β (5 ng/mL) for 6 hours, followed by assays for luciferase and β-gal activity as described previously (29).

Animal treatments. Female 8-week-old Swiss-Webster mice, weighing 25–30 g, were fed standard mice chow pellets and had access to tap water. Acute colitis was induced by feeding the mice 4% dextran sodium sulfate (DSS; molecular mass = 30–40 kDa dissolved in drinking water) for 7 days. Two treatment studies were performed, one with troglitazone (Rezulin; Parke-Davis, Morris Plains, New Jersey, USA) and the other with BRL 49653. The 2 studies contained 8 animals in each treatment group. In the first protocol, troglitazone was suspended in 0.75% methylcellulose solution. Zero, 10, 30, and 100 mg/kg/d of troglitazone (0.1 mL/mouse) was administered by gavage on the day DSS feeding was initiated. After induction of colitis, DSS was discontinued on day 7. Therapy with troglitazone was continued until the mice were sacrificed on day 15. In the second protocol, colitis was initiated with DSS for 7 days, followed by therapy with BRL 49653 (suspected in 0.75% methyl-
cellulose at 0 or 20 mg/kg/d gavaged orally) for an additional 8 days, at which time the animals were sacrificed for histological analysis. A disease activity index (DAI) was determined on a daily basis for each animal, and consists of a calculated score based on change in body weight, stool consistency, and intestinal bleeding as described previously (30). Parameters for the DAI were measured by an investigator (A. Flanigan) blinded to the protocol. A significant decrease in the DAI is considered an end point of successful therapy.

Histology and immunohistochemistry. Mouse colonic tissues embedded in OCT were cut into 5-μm sections and dried and fixed in 4% paraformaldehyde. After a rinse in 1× PBS, they were treated with 1.5% H2O2 in methanol for 20 minutes at room temperature. The sections were then microwaved for 12 minutes in 10 mM citrate acetate (pH 6.0). Blocking was performed for 10 minutes with 1× PBS containing 5% normal goat serum, and the sections were incubated with an affinity-purified polyclonal antibody for PPAR-γ (31) at 1:500 dilution for 30 minutes. After washing with 1× PBS, the slides were incubated with a biotinylated goat anti-rabbit secondary antibody (Vector Laboratories, Burlingame, California, USA) at a dilution of 1:200 for 30 minutes. Staining was detected by using the horseradish peroxidase VECTASTAIN Elite ABC kit (Vector Laboratories) and 3,3′-diaminobenzidine (DAB; Sigma Chemical Co., St. Louis, Missouri, USA). The slides were counterstained in hematoxylin, dehydrated in ethanol and xylene, and mounted with mounting media. Blocking experiments used 10 μg of immunogen peptide preincubated with the PPAR-γ antibody at 4°C overnight.

Results

Treatment of the Caco-2 intestinal cell line, previously shown to express PPAR-γ, with 15d-PGJ2 strongly inhibited IL-1β–induced expression of both the neutrophil chemoattractant IL-8 and MCP-1 (Figure 1a). The average of 3 independent experiments showed this inhibitory effect to be dose dependent, with an EC50 of 12 μM (Figure 1b), which is near the Kd of 15d-PGJ2 binding to PPAR-γ (15, 32). 15d-PGJ2 also inhibited the induction of IL-8 expression in a second intestinal cell line, HT-29, in response to stimulation with either IL-1β (Figure 1c) or TNF-α (data not shown). A different ligand for PPAR-γ, the TZD BRL 49653, also inhibited IL-8 gene expression in a dose-dependent fashion, with an EC50 of 10–50 μM (Figure 1d). Interestingly, although the PPAR-α isoform has been shown to be expressed in colon cancer cell lines (33), treatment of either Caco-2 or HT-29 cells with the PPAR-α–specific ligand WY 14643 did not inhibit the expression of IL-8 (data not shown). This finding is direct contrast to that observed in vascular smooth muscle cells, where ligands for PPAR-α, but not PPAR-γ, inhibit the inflammatory response (34). Therefore, although both PPAR-α and PPAR-γ heterodimerize with retinoic X receptor and bind to similar cis-acting elements, their effects on immune responsiveness appear to be tissue specific.

We next investigated the mechanism by which PPAR-γ ligands inhibit IL-8 gene expression in colon cancer cells. Consistent with its effect on IL-8 gene expression, 15d-PGJ2 inhibited the ability of IL-1β to activate a reporter gene regulated by the IL-8 promoter in a dose-dependent fashion (Figure 2a). Moreover, the EC50 of 25 μM for inhibition of the IL-8 promoter showed excellent agreement with the activation of transcription from a well-characterized positive PPAR-γ response element from the acyl-CoA oxidase gene (27), strongly suggesting that the effects of the ligand are mediated by PPAR-γ. Differences
Figure 3
PPAR-γ ligands inhibit inflammation and reduce disease severity in the DSS model of murine colitis. (a) Colitis was established after 7 days of 4% DSS. Day 0 refers to the day that DSS treatment ended. Throughout the entire course of the study, the mice were treated with the amounts of troglitazone indicated. A DAI was determined daily for each animal in the study. *P = 0.009, **P = 0.003 by unpaired t test. (b) Colitis was established after 7 days of 4% DSS. Day 0 refers to the day that DSS treatment ended and BRL 49653 administration was begun. *P = 0.001, **P = 0.008.

Immunohistochemistry of the normal colon showed that PPAR-γ is expressed predominantly by epithelial cells located in the proliferative crypt compartment (Figure 4a). The specificity of this nuclear staining was confirmed by effective competition using the immunogen peptide. Immunohistochemistry was also performed on tissues obtained from animals treated with DSS (Figure 4b). Colonic tissue from animals that received vehicle alone showed intense mucosal inflammation with a chronic inflammatory infiltrate, edema, and marked thickening of the bowel wall. In contrast, histological sections from the colon of animals treated with 8 days of BRL 49653 showed a remarkable decrease in inflammation with only a mild inflammatory infiltrate, no edema, and normal bowel wall thickness. Immunostaining of these tissue sections demonstrated that PPAR-γ was expressed primarily in the colonic epithelium, even in the presence of intense inflammation (Figure 4b). The inflammatory cells expressed comparatively little PPAR-γ, consistent with the colonic epithelium being the target of PPAR-γ ligands.

Discussion
There is significant interest in the biologic consequences of PPAR-γ activation in the colon. Because of the differentiating and antiproliferative effects of PPAR-γ in adipose and breast tissue (17, 18, 36, 37), it has been proposed that ligands for this receptor may have therapeutic potential in chemoprevention or the treatment of colorectal neoplasia (21, 24). Recent studies, however, suggest that these same ligands actually
enhance colon polyp and tumor formation in the min mouse model of familial adenomatous polyposis coli (22, 23). Here we show that PPAR-γ ligands have another major effect on colon epithelial cells, namely, to regulate the inflammatory response. Several historical observations are consistent with the possible utility of PPAR-γ activation in the treatment of colonic inflammation. First, polyunsaturated fatty acids, such as provided in fish oil, have been shown to be potent activators of PPAR-γ and to have efficacy in the treatment of IBD (38, 39). Second, there is evidence that TZDs may decrease insulin resistance by decreasing the production of TNF-α by adipose tissue and/or by inhibiting TNF-α–mediated signal transduction (40). Inhibition of TNF-α activity by the use of anti-TNF antibodies has been shown to be an effective treatment modality for refractory Crohn’s disease (41).

We show that 2 different classes of ligands for PPAR-γ potently inhibit cytokine expression in 2 different PPAR-γ–expressing colon cell lines (21, 24). The increased potency of 15d-PGJ2 relative to BRL 49653 contrasts with the direct binding affinities of these compounds for PPAR-γ, but is consistent with the relative potencies of these compounds for negative regulation of genes involved in the inflammatory response (12, 13). At present, it is not known why the EC50 for BRL 49653 is greater than that for 15d-PGJ2. It is possible that cofactors necessary for transcriptional repression interact with ligand-bound PPAR-γ differently than those involved in transcriptional activation (42). We also do not exclude the possibility that these compounds inhibit cytokine gene expression through additional mechanisms independent of PPAR-γ. Indeed, a PPAR-γ–independent pathway may be operative in neuronal cells, where investigators have recently shown that 15d-PGJ2 inhibits inducible nitric oxide synthase (iNOS) expression and promoter activity by inhibiting transcriptional activation via NF-κB (43). iNOS expression in microglial cells was not inhibited by TZDs, and the nuclear translocation and DNA-binding activities of NF-κB were unaf-

**Figure 4**

PPAR-γ expression is localized specifically to the colonic epithelium in normal and inflamed tissue. (a) Immunohistochemistry for PPAR-γ was performed on frozen sections of normal mouse colonic tissue. A peptide blocking experiment is shown on the right. (b) Detection of PPAR-γ by immunohistochemistry in colonic tissue obtained from mice treated for 8 days with either vehicle alone or BRL 49653 (20 mg/kg/d). ×100. MP, muscularis propria; SM, submucosa.
fected by 15d-PGJ2. These results, however, are distinctly different from our findings in intestinal cell lines, where BRL 49653 does inhibit IL-8 expression. Furthermore, we show that in Caco-2 cells, 15d-PGJ2 inhibits the nuclear translocation and subsequent DNA binding of NF-κB via an IkB-α–dependent pathway by inhibiting the immune response–induced degradation of IkB-α. This is also distinct from the putative non-PPAR pathway of iNOS regulation in neuronal cells. Although further investigation will be required to elucidate the upstream mechanisms by which PPAR-γ inhibits the degradation of IkB-α, inhibition of both IL-1β– and TNF-α–induced IL-8 gene expression suggests that activation of PPAR-γ alters functional elements common to both these pathways. Targeting of NF-κB as a therapeutic approach to IBD is already established (44).

Although previous studies have shown that activation of PPAR-γ inhibits the inflammatory response in monocytes and macrophages, immunolocalization of PPAR-γ primarily to colonocytes, even in the presence of inflammation, strongly suggests that these epithelial cells are the target of PPAR-γ ligands in this model. This provides evidence that immunomodulation of the intestinal epithelium alone may be efficacious in the treatment of intestinal inflammatory states. We do not exclude the possibility that a component of the anti-inflammatory effect is mediated by the action of TZDs on the systemic immune system. However, the fact that DSS administered rectally can also induce colitis suggests that the inflammatory response is initiated by an effect localized to the colon rather than involving an alteration in the systemic immune system. The role that PPAR-γ ligands may play in neoplasia need not be necessarily viewed as a disparate effect. Indeed, it is well known that chronic intestinal inflammation not only alters patterns of cellular proliferation and differentiation in the intestinal epithelium, but is also a significant factor in the development of colorectal neoplasia (45, 46). At the present time, the effect of PPAR-γ agonists on colonic epithelial cell growth is controversial. Two studies show that these ligands have potent antineoplastic and antiproliferative activities both in vivo and in vitro (21, 24). In contrast, the 2 studies showing that TZD ligands increase the number of colonic polyps utilize the min mouse model of intestinal polyposis (22, 23). The proneoplastic effect observed, therefore, occurs in a single murine model related to an adenomatous polyposis coli gene (APC) mutation. The relevance of the min mouse model to IBD is uncertain, particularly because APC mutations are rare in colitis-induced neoplasia (47). Furthermore, highly unsaturated fatty acids, which are known natural ligands for PPAR-γ, are well known not only to reduce the risk of colonic tumors, but also as an effective treatment for intestinal inflammation (38, 48, 49), supporting the anti-neoplastic role of PPAR-γ. At this point, therefore, it is premature to conclude that PPAR-γ ligands will induce colonic neoplasia in any background, but particularly in the setting of intestinal inflammation. In fact, an equally compelling case could be made that these compounds may protect against the development of neoplasia associated with colitis. Further investigation into the effect of PPAR-γ ligands on neoplastic transformation in the setting of IBD may provide important insights into the biology of the colonic epithelium.

PPAR-γ ligands represent a novel approach to the treatment of IBD. The TZD ligands used in the animal studies were well within the doses needed for insulin sensitization and have been shown to be well tolerated by rodents (21). The DAI s used to quantitate disease activity in our animal studies are comprehensive functional measures that are analogous to the subjective clinical symptoms observed in humans with ulcerative colitis. Many anti-inflammatory pharmaceuticals have been studied in the DSS model of colitis that show efficacy paralleling the clinical response observed in humans (30, 50–53). In fact, the results with either troglitazone or BRL 49653 show a greater level of therapeutic efficacy than that observed with Olsalazine (Dipentum; Pharmacia and Upjohn, Kalamazoo, Michigan, USA) (150 mg/kg/d) (51). Therefore, the highly significant anti-inflammatory effect observed with the DSS model provides the single best indication that PPAR-γ ligands may have clinical efficacy in patients with IBD.

Acknowledgments
This work was supported by National Institutes of Health grants DK-47709 and AI-39368 (to G.D. Wu); Center Grant P30 DK-50306; DK-49780 and DK-49210 (to M.A. Lazar).


